Microbix Biosystems Inc. (TSX:MBX)
Canada
· Delayed Price · Currency is CAD 0.230
0.00 (0.00%)
At close: Mar 6, 2026
Microbix Biosystems Income Statement
Financials in millions CAD. Fiscal year is October - September.
Millions CAD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | 2020 - 2016 |
| Revenue | 16.76 | 18.59 | 25.39 | 16.51 | 19.08 | 18.59 | Upgrade
|
| Revenue Growth (YoY) | -27.22% | -26.81% | 53.77% | -13.43% | 2.60% | 76.66% | Upgrade
|
| Cost of Revenue | 8.93 | 8.73 | 10 | 9.03 | 7.95 | 7.55 | Upgrade
|
| Gross Profit | 7.83 | 9.85 | 15.39 | 7.48 | 11.12 | 11.04 | Upgrade
|
| Selling, General & Admin | 9.15 | 9.1 | 9.37 | 8.17 | 6.72 | 5.17 | Upgrade
|
| Research & Development | 2.29 | 2.33 | 2.13 | 2.05 | 1.8 | 1.03 | Upgrade
|
| Operating Expenses | 11.44 | 11.43 | 11.49 | 10.22 | 8.51 | 6.21 | Upgrade
|
| Operating Income | -3.6 | -1.58 | 3.9 | -2.74 | 2.61 | 4.84 | Upgrade
|
| Interest Expense | -0.97 | -0.95 | -0.92 | -0.84 | -0.83 | -1.6 | Upgrade
|
| Interest & Investment Income | 0.31 | 0.35 | 0.69 | 0.46 | 0.08 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.06 | -0.13 | 0.01 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | - | -0 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -4.33 | -2.3 | 3.67 | -3.12 | 1.87 | 3.23 | Upgrade
|
| Asset Writedown | - | - | - | 3.08 | - | - | Upgrade
|
| Pretax Income | -4.33 | -2.3 | 3.67 | -0.04 | 1.87 | 3.23 | Upgrade
|
| Income Tax Expense | -0.06 | -0.06 | 0.15 | - | 0.08 | - | Upgrade
|
| Net Income | -4.27 | -2.25 | 3.52 | -0.04 | 1.79 | 3.23 | Upgrade
|
| Net Income to Common | -4.27 | -2.25 | 3.52 | -0.04 | 1.79 | 3.23 | Upgrade
|
| Net Income Growth | - | - | - | - | -44.68% | - | Upgrade
|
| Shares Outstanding (Basic) | 140 | 139 | 138 | 138 | 135 | 115 | Upgrade
|
| Shares Outstanding (Diluted) | 140 | 139 | 138 | 138 | 142 | 142 | Upgrade
|
| Shares Change (YoY) | 1.38% | 0.48% | 0.42% | -2.67% | 0.00% | 35.14% | Upgrade
|
| EPS (Basic) | -0.03 | -0.02 | 0.03 | -0.00 | 0.01 | 0.03 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.02 | 0.03 | -0.00 | 0.01 | 0.03 | Upgrade
|
| EPS Growth | - | - | - | - | -49.98% | - | Upgrade
|
| Free Cash Flow | -4.24 | -0.88 | 2.71 | -2.11 | 1.44 | 0.86 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.01 | 0.02 | -0.01 | 0.01 | 0.01 | Upgrade
|
| Gross Margin | 46.74% | 53.02% | 60.61% | 45.30% | 58.32% | 59.40% | Upgrade
|
| Operating Margin | -21.49% | -8.48% | 15.35% | -16.57% | 13.68% | 26.01% | Upgrade
|
| Profit Margin | -25.48% | -12.08% | 13.86% | -0.24% | 9.38% | 17.39% | Upgrade
|
| Free Cash Flow Margin | -25.30% | -4.72% | 10.68% | -12.78% | 7.55% | 4.65% | Upgrade
|
| EBITDA | -2.24 | -0.14 | 5.19 | -1.9 | 3.33 | 5.39 | Upgrade
|
| EBITDA Margin | -13.39% | -0.75% | 20.46% | -11.48% | 17.45% | 28.97% | Upgrade
|
| D&A For EBITDA | 1.36 | 1.44 | 1.3 | 0.84 | 0.72 | 0.55 | Upgrade
|
| EBIT | -3.6 | -1.58 | 3.9 | -2.74 | 2.61 | 4.84 | Upgrade
|
| EBIT Margin | -21.49% | -8.48% | 15.35% | -16.57% | 13.68% | 26.01% | Upgrade
|
| Effective Tax Rate | - | - | 4.10% | - | 4.14% | - | Upgrade
|
| Revenue as Reported | 16.76 | 18.59 | 25.39 | 16.51 | 19.08 | 18.59 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.